Melissa Kalaher, MD
Family Medicine · San Antonio, TXNPI 1629161765
Payments from drug & device makers
Across 238 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$193
- Amgen$184
- Pfizer$152
- Novo Nordisk$152
- Takeda Pharmaceuticals U.S.A., Inc.$129
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 107 | $1,450 |
| Lilly USA, LLC | 11 | $193 |
| Amgen | 10 | $184 |
| Pfizer | 10 | $152 |
| Novo Nordisk | 11 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $129 |
| AstraZeneca | 9 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $128 |
| Astellas Pharma US Inc | 7 | $126 |
| Boehringer Ingelheim | 7 | $107 |
| Novartis | 6 | $94 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Nestle Healthcare Nutrition Inc. | 5 | $82 |
| Johnson & Johnson | 5 | $74 |
| Abbott | 3 | $67 |
| Amarin Pharma, Inc. | 4 | $64 |
| Biohaven Pharmaceuticals, Inc. | 4 | $60 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| Shire North American Group Inc | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Lundbeck LLC | 2 | $31 |
| GE HealthCare | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$124
How this compares
$3,566 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $105,701 |
| EliquisApixaban | 67 | $77,887 |
| JardianceEmpagliflozin | 53 | $61,180 |
| TrulicityDulaglutide | 33 | $56,046 |
| MounjaroTirzepatide | 38 | $39,718 |
| JanuviaSitagliptin Phosphate | 24 | $23,337 |
| MyrbetriqMirabegron | 12 | $16,131 |
| LinzessLinaclotide | 18 | $14,498 |
| FarxigaDapagliflozin Propanediol | 11 | $14,383 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $12,553 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,271 |
| EntrestoSacubitril/Valsartan | 17 | $9,439 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $8,309 |
| VascepaIcosapent Ethyl | 13 | $6,617 |
| Gabapentin | 199 | $5,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $152 | $105,70179 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $193 | $95,76571 claims |
| PfizerEliquis | $152 | $77,88767 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $107 | $69,48966 claims |
| AbbVieLinzess, Synthroid | $1,450 | $16,20838 claims |
| Astellas Pharma US IncMyrbetriq | $126 | $16,13112 claims |
| AstraZenecaFarxiga | $129 | $14,38311 claims |
| GSKBreo Ellipta | $12 | $12,55314 claims |
| NovartisEntresto | $94 | $9,43917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Douglas DenhamSan Antonio$68.5M
- George AtieeSan Antonio$19.9M
- Leonel ReyesSan Antonio$4.3M
- Brian MacgillivraySan Antonio$3.2M
- Juan GarzaSan Antonio$2.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.